Visceral leishmaniasis related to infliximab administration [6];Leishmaniasis visceral con relación a la administración de infliximab

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 22, Issue 5, 2004, Pages 310-

  Romaní Costa, Verónica ^a   Sánchez, Carlos ^a   Moyá, Francesca ^a   Estany, Cristina ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; MEGLUMINE ANTIMONATE; STIBOGLUCONATE SODIUM;

ADULT; CASE REPORT; DIABETES MELLITUS; FOOD AND DRUG ADMINISTRATION; HEPATOMEGALY; HUMAN; LEISHMANIA DONOVANI; LETTER; MALE; MYCOBACTERIUM TUBERCULOSIS; POLYARTHRITIS; PSORIASIS; SPLENOMEGALY; VISCERAL LEISHMANIASIS;

EID: 2942564037     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13059832     Document Type: Letter

References (4)

1. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α -neutralizing agent. N Engl J Med 2001;345:1098-104.
2. Pintado V, Martín-Rabadán P, Rivera ML, Moreno S, Bouza E. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. Medicine 2001; 80:54-73.
3. Flynn JL, Goldstein MM, Chan J, Triebold KL, Pfeffer K, Lowenstein CJ, et al. Tumor necrosis factor- α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995;2:561-72.
4. Murray HW, Jungbluth A, Ritter E, Montelibano C, Marino MW. Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. Infect Immun 2000;68:6289-93.